Annual report pursuant to Section 13 and 15(d)

Note 13 - Supplemental Disclosures of Cash Flow Information and Noncash Investing and Financing Activities (Details Textual)

Note 13 - Supplemental Disclosures of Cash Flow Information and Noncash Investing and Financing Activities (Details Textual) - USD ($)					12 Months Ended
	Mar. 14, 2016	Jul. 08, 2015	Nov. 03, 2014	Apr. 30, 2014	Jun. 30, 2016	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2013
Cliniqa [Member]
Business Combination, Consideration Transferred					$ 82,888,000
Payments to Acquire Businesses, Net of Cash Acquired		$ 83,000,000			82,888,000
Business Combination, Consideration Transferred, Liabilities Incurred					0
Zephyrus [Member] \| Instruments Sales Contingency [Member]
Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High	$ 3,500,000				3,500,000
Zephyrus [Member]
Business Combination, Consideration Transferred					11,530,000
Payments to Acquire Businesses, Net of Cash Acquired					8,030,000
Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High	7,000,000
Payments to Acquire Businesses, Gross	$ 8,000,000
Business Combination, Consideration Transferred, Liabilities Incurred					0
Novus Holdings, LLC [Member]
Business Combination, Consideration Transferred					60,122,000	$ 60,000,000
Payments to Acquire Businesses, Net of Cash Acquired					60,122,000
Business Combination, Consideration Transferred, Liabilities Incurred					0
ProteinSimple [Member]
Business Combination, Consideration Transferred					300,053,000	300,000,000
Payments to Acquire Businesses, Net of Cash Acquired					300,053,000
Business Combination, Consideration Transferred, Liabilities Incurred					0
CyVek, Inc. [Member]
Business Combination, Consideration Transferred					94,927,000	95,000,000
Payments to Acquire Businesses, Net of Cash Acquired					59,927,000
Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High						35,000,000
Payments to Acquire Businesses, Gross			$ 62,000,000			$ 62,000,000
Business Combination, Consideration Transferred, Liabilities Incurred					0
Bionostics [Member]
Business Combination, Consideration Transferred					103,149,000		$ 103,000,000
Payments to Acquire Businesses, Net of Cash Acquired					103,149,000
Business Combination, Consideration Transferred, Liabilities Incurred					0
PrimeGene [Member]
Business Combination, Consideration Transferred					18,761,000		18,700,000
Payments to Acquire Businesses, Net of Cash Acquired				$ 6,000,000	6,031,000
Payments to Acquire Businesses, Gross							6,000,000
Business Combination, Consideration Transferred, Liabilities Incurred					$ 12,730,000		12,700,000
Surrender of Common Stock [Member]
Conversion of Stock, Shares Issued					306	309
Payments to Acquire Businesses, Net of Cash Acquired					$ 91,423,000	$ 420,102,000	109,180,000
Income Taxes Paid, Net						$ 42,600,000	$ 55,200,000	$ 51,600,000
Conversion of Stock, Shares Issued					494	385	1,077
Conversion of Stock, Amount Converted					$ 31,000	$ 31,000	$ 56,000
Conversion of Stock, Shares Converted							733